Once-monthly subcutaneous olanzapine LAI requires no loading doses, oral supplementation, or post-injection monitoring, based on phase 3 SOLARIS data.
Patrick Campbell
Advertisement
Mr Campbell is the vice president of content at MJH Life Sciences.
Articles by Patrick Campbell
Retrospective cohort study of 1305 adults finds specialized virtual behavioral health care produced clinically meaningful gambling symptom improvement within 14 days.
A first-in-vivo PET study finds M1 receptor availability reduced 13% to 19% across brain regions in schizophrenia, strengthening the case for muscarinic-targeted treatment.
Northwestern researchers identify a reduced CSF protein signal in schizophrenia and show a synthetic version restores brain circuit activity in mice.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Psychiatric Times
1
Antipsychotic Plasma Levels in Schizophrenia: Detecting Nonadherence and Guiding Dose Decisions
2
Choosing an Antidepressant: Art, Science, and Knowing Your Patient
3
Can Durable Response to Psilocybin Reshape Treatment-Resistant Depression Care?
4
Responding to Intimate Partner Violence Disclosures in Psychiatry
5